Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.
Pharma & Biotech
Pharma & Biotech
Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Pharma & Biotech
Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Pharma & Biotech
ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?
ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.
Medical Devices & Diagnostics
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.
Pharma & Biotech
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.
Pharma & Biotech
Zentalis Pharmaceuticals aligns DENALI and ASPENOVA trials with evolving ovarian cancer treatment landscape
Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.
Medical Devices & Diagnostics
Could RenovoRx be building a stronger medtech oncology moat through global patent expansion?
Could RenovoRx’s Japan patent strengthen the RenovoCath oncology moat? Read the full PDN analysis on commercial risks, adoption, and global expansion.
Pharma & Biotech
What BioXcel Therapeutics’ latest BXCL501 milestone could mean for neuropsychiatric care
Find out how BioXcel Therapeutics’ BXCL501 study could reshape acute stress care and influence future neuropsychiatric treatment pathways.